INTRODUCTION {#s1}
============

Epigenetic changes are reversible rearrangements of chromatin capable of modulating gene expression in the cell without altering DNA sequence. Acetylation is the most widely studied post-translational modification of histones \[[@R1]\] and results from the balanced activity of two families of enzymes, namely the histone acetyltransferases (HATs) and histone deacetylases (HDACs) catalyzing acetylation/deacetylation of histones, respectively, and thereby providing DNA accessibility to transcription factors \[[@R2]--[@R5]\].

In cancer cells HDACs are typically overexpressed \[[@R6]--[@R9]\] and represent, therefore, the targets for diverse natural/synthetic compounds acting as HDAC-inhibitors (HDACis) \[[@R10]--[@R12]\]. Some of them have successfully been used in the clinic, either alone or in combination with conventional cytotoxics, as potent antineoplastic drugs to support current therapy \[[@R10], [@R11], [@R13]\]. Indeed, HDACis have proven effective in promoting cell cycle arrest and apoptosis in various types of tumours through the generation of reactive oxygen species, activation of caspase cascade, disruption of mitochondrial integrity, increase in autophagy \[[@R10]\], and suppression of pro-survival pathways \[[@R14], [@R15]\]. These events were at least in part mediated by acetylation of histones and nonhistone key regulatory proteins \[[@R16]\] including p53, GATA1, GATA2, retinoic acid receptor, NF-kB and cytoskeletal proteins like α-tubulin \[[@R17]--[@R19]\].

Previously, we described a new series of HDACis generated through the hybridization of 1,4-benzodiazepine (BDZ) ring with SAHA or oxamflatin \[[@R20]\] yielding compounds that displayed powerful anticancer properties against human malignant cells of acute myeloid leukemia \[[@R21]\], prostate adenocarcinoma \[[@R22]\], metastatic melanoma \[[@R15]\] and, notably, were safe to normal mice *in vivo* up to high dosages \[[@R15], [@R21]\].

The study herein aimed at evaluating the effectiveness of a specific HDACi, termed (S)-2, towards human colorectal cancer (CRC) cells HCT116 (and partly also HT-29 and HCT8) *in vitro* and at describing mechanisms underlying drug-induced cell growth arrest and apoptosis. Moreover, the drug showed to be also effective *in vivo* by contrasting HCT116 cell growth in mice xenografts.

Our results point to a crucial involvement of serine/threonine phosphatases and, in particular, of their physiological inhibitors, as mediators of anticancer properties of (S)-2 in CRC cells. Furthermore, these findings disclose a new role for HDAC1 in governing transcription of the oncogenic *Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)* that is known to be overexpressed in numerous cancers \[[@R23], [@R24]\] including CRCs \[[@R25]\]. To our knowledge, such a molecular link between HDAC1 and CIP2A has not been reported previously and may help, therefore, to understand the widespread anticancer effectiveness of several HDACis, including (S)-2, that recognize HDAC1 as a specific target.

RESULTS {#s2}
=======

(S)-2 prompts growth arrest and apoptosis in HCT116 colorectal carcinoma cells {#s2_1}
------------------------------------------------------------------------------

The BDZ-hydroxamate hybrid (S)-2 was assayed for its HDAC-inhibitory activity by using the human colorectal cancer cell line HCT116 as the primary model. Western blot analyses showed that incubation of cultures with 5 μM (S)-2 enhanced histone H3 acetylation and prompted *de novo* acetylation of both H4 and α-tubulin (Figure [1A](#F1){ref-type="fig"}). These effects were observed as early as at 6 h and remained steady up to 48 h of treatment, and were accompanied by a dose-dependent cell growth arrest (Figure [1B](#F1){ref-type="fig"}). Moreover, typical HCT116 culture monolayers underwent morphological changes upon incubation with (S)-2 that induced a marked cell detachment from the substrate, while the residual attached cells displayed a fairly enlarged phenotype (Figure [1C](#F1){ref-type="fig"}). In addition, a 48 h-exposure of HCT116 cultures to 5 μM (S)-2 modified cell cycle progression as indicated by a nearly three-fold increase of cells arrested in G2/M-phase relative to control, and a large decrease of cell population in S-phase (from about 37% of controls to 7.2% of treated cultures) (Figure [1D](#F1){ref-type="fig"}). Besides, about half of HCT116 treated cells underwent apoptosis as assessed by flow cytometry at 48 h (Figure [1E](#F1){ref-type="fig"}, top); and consistently, western blots analyses of cell extracts from drug-treated cultures showed that (S)-2 caused the cleavage of caspase substrate poly(ADP-ribose) polymerase (PARP), a well-known pro-apoptotic marker (Figure [1E](#F1){ref-type="fig"}, bottom). Moreover, to clarify mechanisms of drug-induced apoptosis in HCT116 cells, we used the pan-caspase inhibitor Z-VAD-fmk that was added in culture at 30 μM concentration just 2 h prior to a 24 h-treatment without/with 5 μM (S)-2. The inhibitor abolished (S)-2-mediated activation of caspase cascade and the cleavage of PARP thus indicating that the apoptotic process developed through a caspase-dependent pathway (Figure [1F](#F1){ref-type="fig"}).

![(S)-2 induced growth arrest and apoptosis in HCT116 cells\
(**A**) HCT116 cells were incubated for 6, 15, 24 and 48 h without/with 5 μM (S)-2 and then processed by Western blot and immunostained for the acetylated histone H3/H4 and nonhistone protein acetyl-α-tubulin, while α-tubulin as such was taken as the loading control. (**B**) Cells (10^5^/well) were seeded in 6-well plates and allowed to attach overnight. The day after, increasing amounts of (S)-2 (0, 2.5 and 5 μM) were added to the wells and viable cells (trypan blu-negative) were counted with the aid of a Bürker chamber at the indicated time points (results were the mean ± SD of experiments done in quadruplicate). (**C**) Phase contrast pictures of companion cultures showed that (S)-2 induced morphological changes and a marked decrease in cell density (a typical experiment out of three). (**D**) For cell cycle distribution HCT116 cultures were treated without/with 5 μM (S)-2 for 48 h and then incubated with a PI/RNase solution for 30 min at 4°C prior to the flow cytometric analysis. The percentage of cells in the different phases of the cell cycle was calculated by the ModFit program and shown in each panel were reproduced in three separate experiments. (**E**) top -- Apoptosis in cell cultures treated without/with the drug was also assessed cytofluorimetrically by using the Annexin-V-Fluos/PI assay and the calculated percentages of four different assays yielded comparable values. (E) bottom -- Cell extracts of HCT116 incubated for the indicated time points with 5 μM (S)-2 were subjected to Western immunoblot analysis of the PARP cleaved fragment; GAPDH was the loading control. (**F**) Cell cultures were pre-incubated for 2 h with the pan-caspase inhibitor Z-VAD-fmk (30 μM) and then were treated without/with 5 μM (S)-2 for 24 h. Cell lysates were analyzed by Western immunoblot to detect the cleavage of PARP and of caspase 9; GAPDH was the loading control.](oncotarget-07-25862-g001){#F1}

(S)-2 modulates the GSK-3β/β-catenin signaling pathway {#s2_2}
------------------------------------------------------

An activating mutation of the Wnt/β-catenin pathway is a key oncogenic event occurring in almost all CRCs \[[@R26], [@R27]\]. Due to this specific alteration the GSK-3β-mediated degradation of β-catenin in the cytoplasm is inhibited and this allows the protein accumulation of in the nucleus where it acts as a transcription factor \[[@R28]\]. It seemed interesting, therefore, to explore the effectiveness of (S)-2 on GSK-3β/β-catenin signaling pathway in HCT116 cells. Immunoblot analyses of total cell extracts from cultures incubated up to 48 h with 5 μM (S)-2 showed a time-dependent decrease in the levels of both pGSK-3β(ser9) and active-β-catenin (Figure [2A](#F2){ref-type="fig"}). The evaluation of active β-catenin amounts in total cell lysates as well as in the cytosolic and nuclear fractions after 48 h of treatment proved that the drug caused a significant decrease of total active-β-catenin that, however, was mainly confined to the nucleus (Figure [2B](#F2){ref-type="fig"}). Furthermore, as *c-Myc* and *cyclin D1* are well-known target oncogenes of β-catenin transcriptional activity \[[@R26], [@R28]\] we monitored their expression following treatment without/with 5 μM (S)-2 for 24 h and 48 h, and observed a significant drug-induced decrease of mRNA and protein levels (Figure [2C](#F2){ref-type="fig"}, top and bottom panel, respectively).

![The effects of (S)-2 on GSK-3β/β-catenin pathway\
(**A**) Cell extracts were analyzed by Western blot to detect phospho-GSK-3β(ser9), GSK-3β and active-β-Catenin levels; GAPDH was used as the loading control. (**B**) The total, cytosolic and nuclear extracts of HCT116 cells treated for 48 h without/with 5 μM (S)-2 were obtained (see Materials and Methods) and probed for the active-β-Catenin levels. Purity of the two subcellular fractions was assessed by the presence of GAPDH and fibrillarin as the markers of the cytosolic and nuclear compartment, respectively. (**C**) mRNA and protein levels of c-Myc and cyclin D1 in HCT116 cells treated without/with 5 μM (S)-2 for 24 h and 48 h were determined by quantitative real-time PCR (\*\*\**P* ≤ 0.01) and Western blot, respectively.](oncotarget-07-25862-g002){#F2}

![PP2A is responsible for drug-mediated pGSK-3β dephosphorylation\
(**A**) HCT116 cells transfected with pool-siRNAs towards either *PP1* or *PP2A* for 24 h were incubated for additional 24 h without/with 5 μM (S)-2; then cell extracts were analyzed by Western immunoblot to detect levels of pGSK-3β(ser9), PP1 and PP2A; α-tubulin was used as the loading control. (**B**) HCT116 cell cultures were pre-incubated for 2 h with 50 μM Cantharidin and then treated without/with 5 μM (S)-2 for 24 h. Cell lysates were analyzed by Western blot an probed with specific antibodies against pGSK-3β(ser9) and cleaved PARP fragment; GAPDH was the reference protein. (**C** and **D**) mRNA and protein levels of either I2PP2A and CIP2A from HCT116 cells treated without/with 5 μM (S)-2 were determined at the indicated time points by quantitative real-time PCR (\*\**P* ≤ 0.05; \*\*\**P* ≤ 0.01) and Western blot, respectively.](oncotarget-07-25862-g003){#F3}

PP2A, rather than PP1, plays a role in drug-mediated GSK-3β dephosphorylation {#s2_3}
-----------------------------------------------------------------------------

Once determined that (S)-2 induced GSK-3β activation through serine dephosphorylation, it was important to identify which serine/threonine protein phosphatases could actually be involved. As the bulk of cellular serine/threonine phosphatases is represented by PP1 and PP2A phosphatases \[[@R29]\], their roles in drug-mediated pGSK-3β(ser9) dephosphorylation in HCT116 cells have been investigated with the aid of siRNAs. Western blots of lysates of cells transfected with either *PP1* or *PP2A* specific siRNAs for 24 h and then incubated for additional 24 h without/with 5 μM (S)-2 demonstrated that the down-regulation of *PP1* and *PP2A* led to a marked increase in pGSK-3β(ser9), but only the down-regulation of *PP2A* was really effective in abrogating drug-induced dephosphorylation of pGSK-3β(ser9) (Figure [3A](#F3){ref-type="fig"}). These data were confirmed by experiments carried out with Cantharidin, a chemical inhibitor of PP2A \[[@R30]\], that was added at 50 μM concentration to HCT116 cell cultures 2 h prior to a 24 h-treatment without/with (S)-2. Cantharidin alone prompted a marked increase in pGSK-3β(ser9) and also abolished drug-induced dephosphorylation of pGSK-3β(ser9) and PARP cleavage thus blocking the apoptotic process (Figure [3B](#F3){ref-type="fig"}). Moreover, further information on mechanisms responsible for (S)-2-mediated activation of PP2A were provided by monitoring the expression of its endogenous cellular inhibitors, *i.e.* the inhibitor 2 of protein phosphatase 2A (I2PP2A) and the cancerous inhibitor of protein phosphatase 2A (CIP2A) \[[@R31]\]. Relative mRNA levels of both *I2PP2A* and *CIP2A* underwent a significant time-dependent decrease upon culture treatment with 5 μM drug (Figure [3C](#F3){ref-type="fig"}). Conversely, immunoblot analyses showed that while the amount of I2PP2A was steady along with the experiment, the CIP2A signal decreased at 15 h and more considerably at 24 h thus suggesting that, indeed, this was the phosphatase inhibitor playing a major role in (S)-2-mediated PP2A activation (Figure [3D](#F3){ref-type="fig"}).

(S)-2-induced downregulation of CIP2A is mediated by the inhibition of HDAC1 {#s2_4}
----------------------------------------------------------------------------

The drug-mediated decrease of *CIP2A* expression in HCT116 cells has clearly indicated that HDACs were involved in the regulation of this particular gene; and, therefore, we evaluated the effects of specific siRNAs towards the nuclear histone deacetylase *HDAC1* that we previously reported to be a sensitive target of (S)-2 \[[@R21]\]. Western blot analyses showed that HCT116 cells treated without/with either 5 μM (S)-2 and/or specific *HDAC1* siRNA led to a decrease in CIP2A protein signal (Figure [4A](#F4){ref-type="fig"}), hence suggesting that the drug-induced decrease of CIP2A could actually develop through the inhibition of HDAC1. And, notably, similar changes have also been reproduced in different CRC cell lines such as HT-29 and HCT8. The direct role of HDAC1 in governing CIP2A expression in CRC cells has further been confirmed with the aid of a plasmid harboring the human *CIP2A* full length promoter fused with the *Luc2* luciferase gene. In fact, the downregulation of HDAC1 protein signal by specific siRNA led to a significant decrease of mRNA levels of *Luc2* (Figure [4B](#F4){ref-type="fig"}) due to the silencing the *CIP2A* promoter in all the three CRC cell lines.

![Inhibition of HDAC1 induces CIP2A downregulation\
(**A**) HCT116, HT-29 and HCT8 cell cultures were treated without/with 5 μM (S)-2 for 24 h or transfected with either *HDAC1*-specific and scrambled siRNAs for 48 h. Cell lysates were submitted to Western immunoblot to detect HDAC1 and CIP2A levels; GAPDH was used as the control protein. (**B**) Cells were first treated with *HDAC1*-specific siRNA and scrambled siRNA for 48 h, and then co-transfected with either 1082CIP2ALuc-pGL4.10 or pGL4.10 plasmids and with pGL4.70 up to 16 h. *Luc2* and *Renilla* mRNA levels were determined by quantitative real-time PCR (\*\**P* ≤ 0.05; \*\*\**P* ≤ 0.01).](oncotarget-07-25862-g004){#F4}

(S)-2 greatly reduces HCT116 cell proliferation in mice xenografts {#s2_5}
------------------------------------------------------------------

To assess the *in vivo* anticancer effectiveness of (S)-2 in a xenograft tumor model, HCT116 cells were implanted onto both flanks of nude mice (see legend to Figure [5](#F5){ref-type="fig"} and Materials and Methods for details). A week later, a small swelling was perceived under the skin of some of the animals which were assumed as positively-xenografted mice which were randomized into two groups and then injected *ip* with either the drug or the vehicle (DMSO). Treatments were administered three times a week for the first two weeks and twice in a row on the last week when mice were sacrificed by cervical dislocation. Changes in tumour volumes during along with the experiment were monitored by measurements with a caliper. Tumour mass volumes of (S)-2-treated mice were significantly smaller (average ± 30%) than those of untreated mice (Figure [5A](#F5){ref-type="fig"}, top). Besides, tumour masses of untreated mice were hyperemic and underwent ulceration, whereas those of drug-treated mice did not burst and remained fairly pale in color to suggest that tumour growth elicited only a modest angiogenesis (Figure [5A](#F5){ref-type="fig"}, bottom).

![Tumour xenograft\
(**A**) top -- Aliquots of HCT116 cell suspension (2.5 × 10^6^ cell/100 μl RPMI) were injected subcutaneously in both flanks of male nude mice (see also as Materials and Methods). Positively-xenografted mice were randomized into two groups and then injected *ip* with either the drug or DMSO as the vehicle. Treatments were administered three times a week for the first two weeks and twice in a row on the last week when mice were sacrificed by cervical dislocation. Variations in the tumour volumes along with the experiment and after the sacrifice were measured by a caliper. (A) bottom -- Excised tumours were weighed and volumes were calculated according to the formula (length (mm)) × (width (mm)) × (depth (mm)) × p/6. Statistical analyses of changes in tumour volumes (mean ± SD) after 0, 3, 6 and 8 treatments were as follows: \[for untreated mice: \#0 (25.7 ± 10.0); \#3 (103.3 ± 20.6); \#6 (201.7 ± 64.2); \#8 (188.6 ± 62.1)\] and \[for treated mice: \#0 (28.2 ± 11.7); \#3 (76.1 ± 25.5); \#6 (128.6 ± 26.5); \#8 (142.2 ± 24.7)\]. According to these values the drug was capable of reducing tumour volumes of about 26.4% (1st week), 36.2% (2nd week) and 24.6% (3rd week), as compared to control. Photographs are representative of tumour masses from mice treated with either the vehicle or (S)-2, respectively. (**B**) top -- Immunohistochemistry was performed on specimens of human colon cancer xenografts by using primary antibodies against acetyl-H3 and γ-H2AX, and also the monoclonal antibody MB-1 that recognizes the nuclear marker Ki-67 associated to cell proliferation (see Materials and Methods) followed by a peroxidase-conjugated IgG preparation; 3,3′-diaminobenzidine was employed as the chromogen for development. Slides were counterstained with aqueous Meyer hematoxylin and mounted with glycerol for visual inspection and photography. (B) bottom -- Statistical analyses of data on both top panels of the figure were carried out by Student\'s *t*-test and significant differences between the two groups were indicated by the asterisks (\*\**P* \< 0.05; \*\*\**P* \< 0.01).](oncotarget-07-25862-g005){#F5}

Immunohistochemistry of tumour specimens was performed to determine *in vivo* effects of (S)-2 (Figure [5B](#F5){ref-type="fig"}). We found that the drug exerted its activity within the tumour cells as shown by (a) the presence of acetyl-H3 and γ-H2AX (the latter denoting drug-induced caspase activation and DNA damages) and (b) the marked decrease, as compared to untreated mice, in the amount of tumour cells positively-stained with MIB-1 (against the nuclear marker Ki-67 associated with cell proliferation \[[@R32]--[@R34]\].

DISCUSSION {#s3}
==========

The anticancer properties of (S)-2 towards CRC cells have been thoroughly described in the previous section. Indeed, the drug induced cell cycle arrest and caspase-dependent apoptosis in HCT116 cells and also proved effective *in vivo* by contrasting tumour growth in mice xenografts. However, moving beyond a plain list of all biological and molecular events characterizing the anticancer activity of (S)-2 in CRC cells, we would focus on a specific result that emerged during this study. HDAC1 is an oncogenic protein acting as a transcription factor of various genes \[[@R35]\] among which, however, *CIP2A* was not included previously. *CIP2A* is also an oncoprotein overexpressed in several cancers including CRCs \[[@R25], [@R36]\] where it inhibits the activity of oncosuppressor PP2A that controls cell cycle and apoptosis \[[@R36]--[@R39]\]. PP2A inhibition suppresses the dephosphorylation of pGSK-3β(ser9), thus inhibiting β-catenin degradation and then maintaining the activity of canonical Wnt/β-catenin pathway. Results herein (see the schematic diagram, Figure [6](#F6){ref-type="fig"}) show that the inhibition of HDAC1, by either (S)-2 or specific siRNA, downregulates CIP2A and, therefore, restores the activity of PP2A that dephosphorylates pGSK-3β(ser9). Upon activation, GSK-3β phosphorylates β-catenin that remains confined to the cytosol where it undergoes degradation. The decreased amount/activity of the β-catenin transcription factor induces cell growth arrest by diminishing *c-Myc* and *cyclin D1* expression and abrogating the prosurvival Wnt/β-catenin signaling pathway as well. This is the first time that a direct effect of HDAC1 on *CIP2A* transcription is reported to occur in HCT116, HT-29 and HCT8, thus inferring that this molecular link might be an original signature shared by various types of CRC cells. In this context, the HDACi (S)-2 represented the tool capable of unleashing PP2A activity by inducing HDAC1-mediated downregulation of *CIP2A* transcription in human colon cancers.

![Schematic diagram of (S)-2-induced growth arrest and apoptosis in colon cancer cells\
The oncogenic protein HDAC1 acts as a transcription factor for CIP2A that afterward complexes and inactivates PP2A. The latter becomes unable to dephosphorylate pGSK-3β(ser9) thus allowing the translocation of β-catenin in the nucleus where it induces the transcription of *c-Myc* and *cyclin D1* and, consequently, cell proliferation. The inhibition of HDAC1 by (S)-2 leads to the downregulation of CIP2A expression and, thus, restores the activity of PP2A that dephosphorylates pGSK-3β(ser9). The activated kinase GSK-3β phosphorylates β-catenin that undergoes degradation by the ubiquitin-proteasome system. The decrease in β-catenin levels downregulates *c-Myc* and *cyclin D1* expression and, consistent with this, leads to cell growth arrest.](oncotarget-07-25862-g006){#F6}

MATERIALS AND METHODS {#s4}
=====================

Cell culture and treatments {#s4_1}
---------------------------

Human colon cancer cells HCT116 (CCL-247, ATCC), HT-29 (HTB-38, ATCC) and HCT8 (CCL-244, ATCC), have been cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS, EuroClone, Life Science Division, Milan, Italy) and 2 mM L-glutamine at 37°C in 5% CO~2~ humidified atmosphere. (S)-2 was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, ST. Louis, MO, USA) at 0.1 M concentration and stored in the dark at room temperature (RT). Working drug solutions were obtained by appropriate dilution of the stock solution with the culture medium. The amount of DMSO employed as vehicle did not interfere with drug biological activities. In caspase inhibition experiments Z-VAD-fmk (R&D Systems, Minneapolis, MN, USA) was added in culture 2 h prior to treatment with (S)-2. Cantharidin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) used to inhibit protein phosphatase 2A (PP2A) activity was dissolved in DMSO at 0.1 mM final concentration and stored in −20°C; the inhibitor, at the established concentrations, was delivered to cultures 2 h prior to treatment.

Cell cycle analysis and determination of apoptosis {#s4_2}
--------------------------------------------------

Cell cycle phases were assessed by the propidium iodide (PI)-hypotonic citrate method; apoptosis was measured by the Annexin-V-Fluos/PI test (Roche Molecular Biochemicals, Mannheim, Germany) with the aid of Becton Dickinson FACSCalibur System (Becton-Dickinson, San Jose, CA, USA) \[[@R21]\].

Western blotting {#s4_3}
----------------

Harvested cells were resuspended in 20 mM RIPA buffer (pH 7.4) containing a cocktail of proteinase inhibitors (Calbiochem, Merck, Darmstadt, Germany) and treated by sonication (Microson XL-2000, Minisonix, Farmingdale, NY, USA) to obtain a total protein extract. For cytosol-nucleus fractionation, proteins were isolated by using the ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem) as suggested by the manufacturer. Proteins were assayed by the BCA Protein Assay (Thermo Scientific, Rockford, IL, USA), analyzed by SDS-PAGE and western blotting as reported elsewhere \[[@R40]\]. Membranes were probed with primary antibodies against acetyl-H3, acetyl-H4, active-β-catenin, and PP2A (Upstate Biotechnology, Millipore, Bilerica, MA, USA); acetyl-α-tubulin and α-tubulin (Sigma-Aldrich); GAPDH, cleaved PARP, cleaved caspase-9, c-Myc and phospho-GSK-3β(ser9) (Cell Signaling Technology, Danvers, MA. USA); cyclin D1, GSK-3β, I2PP2A, CIP2A and fibrillarin (Santa Cruz Biotechnology); suitable peroxidase-conjugated IgG preparations (Sigma-Aldrich) were used as secondary antibodies; the ECL procedure was employed for development. Western immunoblots reported all through this work were the mean ± SD of experiments carried out in triplicate (unless otherwise specified) and the software ImageJ \[[@R41]\] was used for densitometric quantification of protein band intensity.

Quantitative real time-PCR analysis {#s4_4}
-----------------------------------

QRT-PCR was performed with reverse transcripted cDNA of either untreated or drug-treated cells by using the Applied Biosystems 7500HT System according to standard protocols. Fold of *c-Myc*, *cyclin D1*, *I2PP2A* and *CIP2A* induction were calculated by the changes of each of their Ct values in treated *vs.* untreated cells and were normalized to the *18S rRNA* Ct values. Amplification was performed with the default PCR setting: 40 cycles of 95°C for 15 sec and of 60°C for 60 sec using a SYBR Green based detection (SYBR Green Master mix; Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) and the following primers: *cyclin D1* forward 5′-CGTGGCCTCTAAGATGAAGG-3′ and reverse 5′-GTGTTCAATGAAATCGTGCGG-3′; *c-Myc* forward 5′-TCAAGAGGTGCCACGTCTCC-3′ and reverse 5′-TCTTGGCAGGATAGTCCTT-3′; *I2PP2A* forward 5′-CGTTCGAGTCAAACGCAGAA-3′ and reverse 5′-CAGCACCTGCATCAGAATGGT-3′; *CIP2A* forward 5′-TGACCCTTCTGCTGCCTACA-3′ and reverse 5′-GCCTTGGCAATCCTTTCACA-3′; *18S rRNA* forward 5′-CGGCTACCACATCAAGGAA-3′ and reverse 5′-GCTGGAATTACCGCGGCT-3.′

siRNAs and plasmids transfection {#s4_5}
--------------------------------

In silencing experiments, 2 × 10^5^ cells were seeded in 60 mm culture dishes 16 h before transfection with siRNAs using 7.5 μl of Lipofectamine RNAiMAX (Invitrogen, Thermo Fisher Scientific). *PP1* (mix of 500 pmol of each \#105828 targeting *PPP1CA*, \#104504 targeting *PPP1CB* and \#105829 targeting *PPP1CC*), *PP2A* (mix of 500 pmol of each \#104510 targeting *PPP2CA* and \#104717 targeting *PPP2CB*), *HDCA1* (500 pmol of \#120418) and non-targeting control siRNA (500 pmol of \#4390844) were from Thermo Fisher Scientific. In over-expression experiments, 2 × 10^5^ cells were seeded into 60 mm dishes 16 h before co-transfection with 2.5 μg of plasmid 1082CIP2ALuc-pGL4.10 (kind gift of Professor Jukka Westermark, University of Turku and Abo Akademi, Turku, Finland) \[[@R42]\] or pGL4.10 (as control, Promega, Fitchburg, WI, USA) and 2.5 μg pGL4.70 (Promega) using 7.5 μl of Lipofectamine LTX (Invitrogen, Thermo Fisher Scientific).

Tumour xenograft model {#s4_6}
----------------------

Male nude (nu/nu) mice (Harlan Laboratories, Srl, San Pietro al Natisone, UD, Italy) were cared for and maintained in accordance with applicable European Animal Welfare regulations under an approved Institutional Animal Care and Use Protocol in an animal facility at University of Florence accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. To establish subcutaneous tumours, aliquots of HCT116 cell suspension (2.5 × 10^6^ cell/100 μl RPMI) were injected subcutaneously on both flanks of 24 mice. A week later the tumour mass was perceived in 14 mice (out of those originally injected), which were then randomized into two equal groups and treated with the drug or the vehicle at the established times. Changes in tumour volumes during the experiment were monitored by regular measurements with a caliper. Eventually, mice were killed by cervical dislocation and tumours were excised, weighed and their volumes were calculated according to the formula (length (mm)) × (width (mm)) × (depth (mm)) × p/6.

Immunohistochemistry {#s4_7}
--------------------

Slides with consecutive 2.5--5 μm sections of paraffin embedded tumour masses were first deparaffinized, boiled in 1 mM EDTA pH 9 for 15 min and after cooling aspecific peroxidases were blocked with 3% H~2~O~2~ for 10 min. Then, slides were treated according to standard procedures and incubated with primary antibody solutions against acetyl-H3 and γ-H2AX (to denote drug-induced caspase activation and DNA damages); and also with the monoclonal antibody MIB-1 (recognizing the nuclear marker Ki-67 that was associated with cell proliferation) (Dako, Glostrup, Danimarca) \[[@R33], [@R34]\] followed by a peroxidase-conjugated IgG preparation; 3,3′-diaminobenzidine (Zymed Laboratories Inc., South San Francisco, CA, USA) was used as the chromogen for development. Slides were counterstained with aqueous Meyer hematoxylin and mounted with glycerol for visual inspection and photography; pictures are representative of four randomly chosen microscopic fields (magnification: ×400) and taken with the aid of a microscope (Nikon Eclipse, mod. 50i) equipped with a digital camera (DS-5 M USB2) (Nikon Instruments, Florence, Italy) as described previously \[[@R22]\].

Statistical analysis {#s4_8}
--------------------

The Student′s *t*-test or one-way analysis of variance have been employed to assess statistical significance of results. The difference among the values was considered significant at *P* ≤ 0.05.
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